NCT01512693View on ClinicalTrials.gov

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 23, 2012

Primary Completion Date

April 24, 2012

Study Completion Date

April 24, 2012

Conditions
Hepatic Insufficiency
Interventions
DRUG

MK-0822

A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01512693 - Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) | Biotech Hunter | Biotech Hunter